Biosyntech Stock Net Income
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Biosyntech's long-term financial health and intrinsic value.
Biosyntech |
Biosyntech Company Net Income Analysis
Biosyntech's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Biosyntech Net Income | (12.94 M) |
Most of Biosyntech's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biosyntech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Biosyntech reported net income of (12.94 Million). This is 103.79% lower than that of the Biotechnology sector and 118.47% lower than that of the Health Care industry. The net income for all United States stocks is 102.27% higher than that of the company.
Biosyntech Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biosyntech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Biosyntech could also be used in its relative valuation, which is a method of valuing Biosyntech by comparing valuation metrics of similar companies.Biosyntech is currently under evaluation in net income category among its peers.
Biosyntech Fundamentals
| Return On Asset | -0.52 | |||
| Operating Margin | (33.33) % | |||
| Current Valuation | 116.44 K | |||
| Shares Outstanding | 116.44 M | |||
| Price To Earning | (0.01) X | |||
| Price To Sales | 0.0006 X | |||
| Revenue | 5.06 K | |||
| Gross Profit | 24.8 K | |||
| EBITDA | (6.32 M) | |||
| Net Income | (12.94 M) | |||
| Cash And Equivalents | 1.44 M | |||
| Cash Per Share | 0.01 X | |||
| Current Ratio | 0.21 X | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (9.57 M) | |||
| Earnings Per Share | (0.1) X | |||
| Target Price | 0.5 | |||
| Beta | 0.12 | |||
| Market Capitalization | 116 | |||
| Total Asset | 893.01 K | |||
| Retained Earnings | (18.04 M) | |||
| Working Capital | (583 K) | |||
| Current Asset | 692 K | |||
| Current Liabilities | 1.27 M | |||
| Z Score | -51.1 | |||
| Net Asset | 893.01 K |
About Biosyntech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biosyntech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biosyntech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biosyntech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Biosyntech Pink Sheet
If you are still planning to invest in Biosyntech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biosyntech's history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |